Menu Search
Equities

Aytu Biopharma Inc

AY20:BER

Aytu Biopharma Inc

Actions
  • Price (EUR)2.42
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Apr 24 2023 12:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Aytu Biopharma Inc has grown net income from a loss of -17.05m to a smaller loss of -15.84m despite declining revenues.
Gross margin67.39%
Net profit margin-19.56%
Operating margin-7.22%
Return on assets-12.45%
Return on equity-47.24%
Return on investment-25.70%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Aytu Biopharma Inc fell by 2.98m. Cash Flow from Investing was negative at 329.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 1.39m for operations while cash used for financing totalled 1.26m.
Cash flow per share-1.37
Price/Cash flow per share--
Book value per share4.64
Tangible book value per share-4.14
More ▼

Balance sheet in USDView more

Aytu Biopharma Inc has a Debt to Total Capital ratio of 35.31%, a lower figure than the previous year's 37.38%.
Current ratio0.9946
Quick ratio0.7916
Total debt/total equity0.5459
Total debt/total capital0.3531
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.